VETOQUINOL overview

Regulatory News: Matthieu Frechin, Chairman and CEO of Vetoquinol (Paris:VETO), commented: "In 2024, we delivered a solid financial year, combining growth in almost all our reference markets, high profitability and sustained cash generation. We have achieved this performance while absorbing the sometimes significant uncertainties, such as in the United States this year, as well as the cost of transforming the Group. This is due to the strength of our model built around Essentials, which have...

Regulatory News: Matthieu Frechin, Chairman and CEO of Vetoquinol (Paris:VETO), commented: " All our activities and territories are growing, with the exception of the United States for one-off reasons. We are on track to deliver long-term profitable growth. We owe this to our focus strategy and the power of our "Essentials" model, which has delivered average annual growth of over 8% for the past 10 years. We will continue to pursue this strategy in 2025. " Vetoquinol's sales for FY 2024 came to...

Regulatory News: Vetoquinol (Paris:VETO) published its calendar of financial communication for 2025. January 30, 2025 2024 Annual Sales (after market) March 20, 2025 2024 Annual results (confcall after market) April 24, 2025 2025 First quarter sales (after market) May 22, 2025 Annual shareholders’ meeting June 6, 2025 Dividend payment September 11, 2025 2025 First semester results (confcall after market) October 28, 2025 2025 Third quarter sales (after market) Next update: Annual Sales 2024,...

Regulatory News: The Vetoquinol (Paris:VETO) saga started 90 years ago in the back office of the Frechin family pharmacy in Lure, Franche Comté (East of France). The company is now among the top 10 animal health companies in the world, nine decades and three generations later, but its DNA is still rooted in Lure, in this Haute-Saône village. Over 700 current and former employees and retirees of the company from Lure and all over France gathered there on June 16, 2023, to commemorate the 90th...

Regulatory News: Vetoquinol (Paris:VETO): Ever since the company was founded in 1933, innovation has been a major component of Vetoquinol's development strategy. Far from limiting itself to finding new active ingredients or new medicines, Research and Development (R&D) has also focused on extending the uses, target species and distribution areas of existing products. Over the years, innovation has enabled the company to focus on strong therapeutic areas and targeted species to make optimal use...

Regulatory News: The Combined General Meeting of Vetoquinol (Paris:VETO) shareholders was held on Thursday 25 May 2023 at the laboratory's head office in Lure (Franche-Comté), chaired by Mr. Etienne Frechin. All the resolutions proposed by the Board of Directors were adopted, including: The statutory and consolidated financial statements for the year 2022 were approved. The dividend per share was set at 0.80 euro. It will be paid as of 6 June 2023. The reappointment of Mr. Philippe Arnold as an...